What's breaking now, across thousands of outlets.
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
The ADT on the NSE fell to a five-month low in August as investors turned cautious amid sharp price volatility and widespread profit-booking
Aon is nearing an agreement to buy insurance brokerage USI Insurance from private equity firm KKR & Co. for around $17 billion, the Wall Street Journal reported, citing people familiar with the…
SpaceX just revealed its main financial engine -- and it's not rockets.
A financial model that could cut the cost of installing solar panels for many homeowners is welcomed by Alexis Abramson The UK proposal to use “solar bonds” to make rooftop solar more affordable is a…
